SCHEMBL4677148

SCHEMBL4677148

Cc1ccc(Cc2nc(CC(=O)C(=O)c3nn[nH]n3)cs2)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.37
TDP1 Q9NUW8 2/20 0.37
HDAC1 Q13547 3/20 0.36
HDAC6 Q9UBN7 3/20 0.36
PTGDR2 Q9Y5Y4 1/20 0.35
CYP1A2 P05177 3/20 0.35
CYP3A4 P08684 3/20 0.35
CYP2C9 P11712 3/20 0.35
CYP2C19 P33261 3/20 0.35
KMT2A Q03164 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
RAB9A P51151 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
BCHE P06276 1/20 0.33
KLKB1 P03952 1/20 0.33
KLK1 P06870 1/20 0.33
CYP2D6 P10635 1/20 0.32
LMNA P02545 1/20 0.32
GAA P10253 1/20 0.32
ALOX12 P18054 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4679324 0.91 ALDH1A1 (0.39) ALDH1A1TDP1HDAC1HDAC6PTGDR2
SCHEMBL4679026 0.89 XDH (0.38) HDAC1HDAC6CYP1A2CYP3A4CYP2C9
SCHEMBL4676878 0.89 HDAC1 (0.39) HDAC1HDAC6CYP1A2CYP3A4CYP2C9
SCHEMBL4676407 0.89 HDAC1 (0.39) ALDH1A1HDAC1HDAC6PTGDR2KMT2A
SCHEMBL4675057 0.89 HDAC1 (0.47) ALDH1A1HDAC1HDAC6KMT2ASMN1; SMN2
SCHEMBL4674866 0.89 LMNA (0.46) ALDH1A1HDAC1HDAC6CYP1A2CYP3A4
SCHEMBL4674232 0.88 HDAC1 (0.37) HDAC1HDAC6HDAC8
SCHEMBL4671892 0.83 BCHE (0.37) ALDH1A1TDP1HDAC1HDAC6PTGDR2
SCHEMBL4676194 0.81 HDAC1 (0.43) HDAC1HDAC6PTGDR2KMT2ASMN1; SMN2
SCHEMBL4680267 0.81 XDH (0.38) HDAC1HDAC6KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6645956-B1 1-(5-(4-fluorobenzyl)furan-2-yl)-3-hydroxy-3-(1H-1,2,4-triazol-3 -yl)-propenone; viricides; AIDS treatment SHIONOGI & CO., LTD. (JP) 2003-11-11 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
CN-1335834-A Aromatic heterocyclic compounds having HIV integrase inhibitory activity SHIONOGI & CO (JP) 2002-02-13 CN disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 ALDH1A1 980/4885TDP1 306/4885HDAC1 250/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.